EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, DBV Technologies's Enterprise Value is $32.33 Mil.
DBV Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-108.72 Mil. Therefore, DBV Technologies's EV-to-FCF for today is -0.30.
The historical rank and industry rank for DBV Technologies's EV-to-FCF or its related term are showing as below:
DBVT'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.77 Med: -1.19 Max: 0.16
Current: -0.31
During the past 13 years, the highest EV-to-FCF of DBV Technologies was 0.16. The lowest was -2.77. And the median was -1.19.
DBVT's EV-to-FCF is ranked worse than 100% of 385
companies
in the Biotechnology industry
Industry Median: 8.82
vs DBVT: -0.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for DBV Technologies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DBV Technologies's EV-to-FCF
For the Biotechnology subindustry, DBV Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where DBV Technologies's EV-to-FCF falls into.
DBV Technologies's current Enterprise Value is $32.33 Mil.
DBV Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-108.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (NAS:DBVT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DBV Technologies's PE Ratio (TTM) for today is calculated as:
DBV Technologies's share price for today is $3.29.
DBV Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
DBV Technologies EV-to-FCF Related Terms
Thank you for viewing the detailed overview of DBV Technologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DBVT has been successfully added to your 